Integrated Investment Consultants LLC decreased its stake in shares of Mednax, Inc (NYSE:MD) by 0.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,660 shares of the company’s stock after selling 20 shares during the period. Integrated Investment Consultants LLC’s holdings in Mednax were worth $281,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in MD. BlackRock Inc. raised its stake in Mednax by 5,766.0% in the first quarter. BlackRock Inc. now owns 8,229,340 shares of the company’s stock worth $570,952,000 after buying an additional 8,089,052 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Mednax by 4.7% in the first quarter. Vanguard Group Inc. now owns 7,512,485 shares of the company’s stock worth $521,216,000 after buying an additional 339,932 shares during the last quarter. FMR LLC increased its position in shares of Mednax by 1.3% in the first quarter. FMR LLC now owns 5,313,581 shares of the company’s stock worth $368,656,000 after buying an additional 68,581 shares during the last quarter. Longview Partners Guernsey LTD increased its position in shares of Mednax by 27.4% in the first quarter. Longview Partners Guernsey LTD now owns 4,555,631 shares of the company’s stock worth $316,070,000 after buying an additional 980,081 shares during the last quarter. Finally, State Street Corp increased its position in shares of Mednax by 2.2% in the first quarter. State Street Corp now owns 2,943,797 shares of the company’s stock worth $204,246,000 after buying an additional 62,812 shares during the last quarter.

Mednax, Inc (NYSE MD) traded down 0.48% during mid-day trading on Thursday, hitting $57.96. The company had a trading volume of 84,028 shares. The company has a market capitalization of $5.35 billion, a P/E ratio of 17.30 and a beta of 0.44. Mednax, Inc has a 52-week low of $53.80 and a 52-week high of $76.96. The company has a 50-day moving average price of $56.38 and a 200 day moving average price of $64.57.

Mednax (NYSE:MD) last posted its quarterly earnings results on Thursday, May 4th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.01. The company had revenue of $835.60 million for the quarter, compared to analyst estimates of $837.01 million. Mednax had a return on equity of 12.81% and a net margin of 9.54%. Mednax’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.87 EPS. On average, analysts forecast that Mednax, Inc will post $3.58 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Integrated Investment Consultants LLC Cuts Position in Mednax, Inc (NYSE:MD)” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/07/13/integrated-investment-consultants-llc-cuts-position-in-mednax-inc-nysemd.html.

MD has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Thursday, April 27th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a research note on Thursday, May 4th. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. TheStreet cut shares of Mednax from a “b-” rating to a “c+” rating in a research note on Tuesday, May 16th. Finally, ValuEngine cut shares of Mednax from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $65.89.

In related news, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the transaction, the insider now owns 296,379 shares in the company, valued at approximately $16,300,845. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the transaction, the director now owns 18,072 shares in the company, valued at approximately $1,040,405.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,074 shares of company stock worth $1,830,508. Company insiders own 2.40% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.